The National Institute on Aging (NIA) established the model organism development and evolution for late-onset Alzheimer’s disease (MODEL-AD), which addresses the following points: (1) to develop new models of LOAD using humanized Aβ and tau to recapitulate human AD pathology, (2) to identify novel genetic variants that increase the risk of LOAD, and (3) to develop a robust preclinical testing line for testing newer therapeutics [109]. Here, MAPT is linked to Alzheimer disease.